1. Zebrafish tumour xenograft models: a prognostic approach to epithelial ovarian cancer
- Author
-
Gabriel Lindahl, Sebastian Fjellander, Karthik Selvaraj, Malin Vildeval, Zaheer Ali, Rusul Almter, Anna Erkstam, Gabriela Vazquez Rodriguez, Annelie Abrahamsson, Åsa Rydmark Kersley, Anna Fahlgren, Preben Kjølhede, Stig Linder, Charlotta Dabrosin, and Lasse Jensen
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Epithelial ovarian cancer (EOC) is the gynaecological malignancy with highest mortality. Although adjuvant treatment with carboplatin and paclitaxel leads to an objective response in ~80% of these patients, a majority will relapse within two years. Better methods for assessing long-term treatment outcomes are needed. To address this, we established safe and efficacious doses of carboplatin and paclitaxel using IGROV-1 zebrafish-CDX models. Then fluorescently-labelled cell suspensions from 83 tumour biopsies collected at exploratory laparotomy of women with suspected EOC were generated and 37 (45%) were successfully implanted in zebrafish larvae. Among these 19 of 27 pathology-confirmed EOC samples (70%) engrafted. These zebrafish patient-derived tumour xenograft (ZTX) models were treated with carboplatin or paclitaxel and tumour growth/regression and metastatic dissemination were recorded. In a subgroup of nine patients, four ZTX models regressed during carboplatin treatment. All four corresponding patients had >24 months PFS. Furthermore, both ZTX models established from two patients having 24 months PFS. In eleven of fourteen patients, FIGO stage I + II or III tumours gave rise to ZTX models seeding 4 metastatic cells, respectively. In conclusion, ZTX models predicted patients having >24 or
- Published
- 2024
- Full Text
- View/download PDF